Business Model & Revenue
Exagen is a Carlsbad, California-based autoimmune diagnostics company that generates revenue primarily through clinical laboratory testing services. Its flagship AVISE CTD (Connective Tissue Disease) panel uses proprietary cell-bound complement activation products (CB-CAPs) and other biomarkers to diagnose and monitor systemic autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's syndrome, and related conditions.
The business model is classic diagnostic testing: physicians order AVISE tests, Exagen's CLIA-certified laboratory processes them, and the company bills Medicare, Medicaid, and private payers on a per-test basis. The trailing-twelve-month ASP is $446 per test, with revenue recognized upon test completion and billing. Gross margins have expanded from 46.9% in 2022 to 61.3% in Q2 2026, reflecting operational leverage as test volume scales the fixed-cost laboratory infrastructure.
Exagen also offers AVISE Lupus, AVISE APS, and AVISE Rheumatoid Arthritis panels. The company is investing in AI-powered rheumatology workflow tools and new biomarker development to expand its testing menu. The go-to-market strategy targets rheumatologists directly through a specialized sales force, emphasizing diagnostic accuracy and clinical evidence — including the systematic review of 3,132 patients validating AVISE Lupus performance.
Financial Highlights
Full-Year Results
| Metric | FY2025 | FY2024 | YoY |
|---|---|---|---|
| Revenue | $66.6M | $55.6M | +19.7% |
| Gross Profit | $38.8M | $33.1M | +17.2% |
| Gross Margin | 58.3% | 59.5% | -120bps |
| Operating Loss | $(14.1)M | $(13.6)M | -3.3% |
| Net Loss | $(20.0)M | $(15.1)M | -32.0% |
| EPS (Diluted) | $(0.93) | $(0.83) | — |
| Cash | $32.2M | $22.0M | +46.2% |
Quarterly Progression
| Quarter | Revenue | Net Loss | Gross Margin |
|---|---|---|---|
| Q2 2026 | $19.9M | $(3.2)M | 61.3% |
| Q1 2026 | $17.3M | $(4.0)M | 59.0% |
| Q4 2025 | ≈$17.4M | — | — |
| Q3 2025 | ≈$16.5M | — | — |
Q2 2026 vs Q2 2025
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $19.9M | $17.2M | +15.9% |
| Gross Margin | 61.3% | 60.4% | +90bps |
| Net Loss | $(3.2)M | $(4.4)M | -27.9% |
| Adjusted EBITDA | $(0.1)M | $(1.7)M | -93.4% |
| TTM ASP | $446 | $428 | +4.2% |
| Test Volume | — | — | +11% |
Balance Sheet (as of June 30, 2026)
| Item | Amount |
|---|---|
| Cash & Equivalents | $24.6M |
| Total Debt | $27.7M |
| Net Cash (Debt) | $(3.1)M |
| Shares Outstanding | 24.2M |
Guidance: FY2026 revenue raised to $72-75M (from $70-73M). Management targets adjusted EBITDA breakeven by year-end 2026.
Competitive Landscape
Exagen operates in the autoimmune disease diagnostics market, projected to exceed $10 billion globally by 2031. The company's niche is specialized autoimmune biomarker testing — a segment where large reference laboratories offer broad menus versus Exagen's focused, evidence-backed AVISE platform.
-
Quest Diagnostics (DGX): The largest U.S. reference laboratory. Offers autoimmune panels within a comprehensive test menu. Competes on scale and payer contracts but lacks Exagen's proprietary CB-CAPs biomarker technology.
-
Labcorp (LH): Similar broad-spectrum reference laboratory with conventional ANA and autoimmune testing. Neither Quest nor Labcorp has replicated the AVISE CTD's clinical evidence base.
-
Myriad Genetics (MYGN): Molecular diagnostics peer focused on hereditary cancer and pharmacogenomics. Relevant as a revenue multiple comp for specialized diagnostic testing at similar revenue scale.
-
Inova Diagnostics (Werfen): Specialized autoimmune diagnostics company with the QUANTA Flash platform. The closest direct competitor to Exagen in automated autoimmune serology.
-
Bio-Techne (TECH): Life science reagents and diagnostics company with autoimmune assay capabilities. Competes at the reagent and assay level rather than as a direct clinical lab.
Competitive moats include: (1) proprietary CB-CAPs technology validated across 14 medical centers and 3,132 patients, (2) rising ASP from $428 to $446 indicating genuine pricing power despite large-lab competition, (3) a rheumatologist-focused sales force with deep clinical evidence, and (4) switching costs once AVISE is embedded in rheumatology diagnostic workflows.
Catalysts
-
Q3 2026 adjusted EBITDA breakeven (expected November 2026): Q2 came in at -$0.1M. A Q3 crossing into positive territory fundamentally reprices the stock from a loss-making micro-cap to a profitable growth company.
-
New biomarker launches: Exagen's pipeline includes anti-RA33, anti-PAD4, and kidney-specific biomarker panels for lupus nephritis and diabetic kidney disease. New test launches expand the addressable market and could drive test volume above the current 10-11% growth trend.
-
AI-powered rheumatology workflow tools: Management cited investment in AI-powered clinical decision support tools that integrate with AVISE testing. If these tools deepen rheumatologist dependency on the Exagen ecosystem, they create a switching-cost moat.
-
Payer coverage expansion: Additional Medicare Local Coverage Determinations or positive private payer policy updates would directly lift both volume through improved access and ASP through favorable reimbursement rates.
-
Full-year 2026 guidance trajectory: With guidance already raised from $70-73M to $72-75M, another upward revision at Q3 would signal sustained momentum and could trigger analyst coverage initiations.
Key Risks
- Competitive pressure from large reference laboratories: Quest Diagnostics and Labcorp can bundle autoimmune panels at lower price points, potentially compressing ASP growth and capturing share through payer channel dominance.
- Balance sheet leverage: $27.7M in total debt against $24.6M cash creates a $3.1M net debt position. If profitability slips beyond Q4 2026, additional financing could be dilutive at current depressed share prices.
- Reimbursement risk: Exagen depends on favorable coverage and reimbursement decisions from Medicare Administrative Contractors and private payers. Any adverse coding or pricing decision could materially impact ASP and volume.
- Low trading liquidity: Average daily volume is approximately 15,000-30,000 shares, creating wide bid-ask spreads and limiting institutional interest. A secondary offering would face significant discount pressure.
- Slowing volume growth: Q2 test volume growth of 11% is solid but not accelerating. If volume growth falls below high single digits, the path to operating leverage narrows and the bull case weakens.
Our Thesis
Exagen owns a defensible niche in autoimmune diagnostics that larger reference laboratories have not replicated. The AVISE CTD test uses proprietary cell-bound complement activation products (CB-CAPs) to diagnose lupus, rheumatoid arthritis, and Sjogren's syndrome with clinically validated superiority over conventional ANA testing. A systematic review of 3,132 patients across 14 medical centers showed AVISE CTD identified approximately 25% of SLE patients missed by standard markers — evidence that drives rheumatologist adoption and supports the 4% ASP expansion to $446 per test. Revenue grew from $45.6M in 2022 to $66.6M in 2025 (13.5% CAGR) and TTM revenue through June 2026 stands at $71.1M (+20.8%).
Our $7.50 target applies a 2.5x price-to-sales multiple to FY2026 guidance midpoint of $73.5M, yielding $183.8M divided by 24.2M diluted shares. This is conservative for a diagnostics company growing 20% with expanding margins — peers like Myriad Genetics trade at 2-4x sales. The gap between GAAP net loss ($3.2M Q2) and adjusted EBITDA (-$0.1M) is stock-based compensation and depreciation, both non-cash. Cash of $24.6M against $27.7M debt provides adequate runway to breakeven, expected within two quarters at the current trajectory.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.